25iP-NBOMe

25I-NBOMe (also known as 2C-I-NBOMe, Cimbi-5 and 25I) is a psychedelic hallucinogen that is used in biochemistry research for mapping the usage of the 5-HT2A receptor in the brain. It is derived from the phenethylamine family and is commonly compared to LSD due to its similar effects and potency.

History[edit | edit source]

25I-NBOMe was first synthesized in 2003 by Ralf Heim at the Free University of Berlin. It later gained popularity in 2010 when it started being sold online, marketed as a research chemical.

Pharmacology[edit | edit source]

25I-NBOMe acts as a highly potent full agonist for the human 5-HT2A receptor, making it a powerful psychedelic. It has a high binding affinity for the 5-HT2A receptor, which is thought to be the primary target for most psychedelic drugs.

Effects[edit | edit source]

The effects of 25I-NBOMe can vary greatly depending on the dose, but typical effects include intense visual hallucinations, distorted perception of time, and euphoria. It can also cause negative effects such as nausea, anxiety, and potentially dangerous increases in heart rate and blood pressure.

Legal Status[edit | edit source]

The legal status of 25I-NBOMe varies by country, but it has been made illegal in many countries due to its potential for abuse and lack of medical use.

References[edit | edit source]

Template:Psychoactive drug-stub

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.